The reporter of the Shanghai Securities News learned from the Medical Department of the Consumer Product Department of the Ministry of Industry and Information Technology，The Ministry of Industry and Information Technology is currently in conjunction with the Food and Drug Administration and other departments，Formulate policies and measures to promote the merger and reorganization of enterprises，Resource integration after supporting corporate mergers and reorganization。
According to Wang Xuegong, the department,，The development of my country's pharmaceutical industry policy in the future includes，Promote the improvement of independent innovation ability，Promote the improvement of the development of generic drugs，and promote mergers and reorganization and increase industrial concentration。"Specific measures include the policy of improving the production approval of drug production in the group。"He revealed。
In the "Pharmaceutical Industry 12th Five -Year Plan", which was introduced earlier this year,，It also clearly promotes the merger and reorganization of enterprises as an important task，The target is to improve industrial concentration，Strive for the top 100 companies' sales revenue account for more than 50%of the industry。
Under the influence of policy favorable，Chinese pharmaceutical industry mergers and acquisitions stake betting appwill Stake Sports Bettingbecome one of the main theme of the "Twelfth Five -Year Plan" stage。
China Pharmaceutical Suction and Tianfang Pharmaceuticals will make pharmaceutical companies and purchase tide
Dested，my country's pharmaceutical industry also purchases the tide to the wind and rises。May 6，Two listed companies owned by China General Technology Group，China Pharmaceutical (600056.SH)、The restructuring plan of Tianfang Pharmaceutical (600253.SH) is finally released after half a year。Chinese pharmaceutical will absorb merged and absorb meteor and Fang Fang Pharmaceutical，Tianfang Pharmaceutical will terminate listing。
According to marketing analysis，The solution to absorb mergers fully reflects that General Technology Group intends to build Chinese medicine as its only listing platform in the pharmaceutical sector，and integrate the group's pharmaceutical resources，Strategic planning for the overall listing of the pharmaceutical sector。Before reorganization，Chinese pharmaceutical focus on commercial circulation and international trade，Tianfang Pharmaceutical focuses on R & D pharmaceutical，After the reorganization, it will achieve complementary advantages and integration of the entire industry chain，To better cope with the current increasingly intense medical competition trend with a unified listing platform。
At the end of March this year，Guangzhou Pharmaceutical (600332) and Baiyunshan A (000522), a subsidiary of Guangye Pharmaceutical Group, both resumed trading and announced the reorganization plan，Guang Pharmaceutical Group will become the second overall listing pharmaceutical platform after Shanghai Medicine，and because the company under Guangyao Group is also in Hong Kong、Shanghai、Listing of the Shenzhen -Three Earth Exchange，Guangyao Reorganization will open the pioneer of domestic asset integration。
Last year，China Biotechnology Group Corporation、Shanghai Pharmaceutical Industry Research Institute merged into China Pharmaceutical Group，China Resources Group reorganized Beijing Pharmaceutical Group and other projects.，A batch of enterprises quickly expand the scale through mergers and acquisitions，Realized the integration My stake betting appof stake online sports bettingthe industrial chain and the adjustment of business layout，Enhance market competitiveness，strongly promoted the optimization of industrial organization structure。In addition，East China Medicine、Listed companies such as Kangzhi Pharmaceutical and Kelun Pharmaceutical are also keen to acquire and reorganize，Solve the contradiction of production capacity，Accelerate product or structural adjustment。
Shenzhen, a listed company investor office engaged in biomedical research and development and production, also told the Shanghai Securities News，Two years today，The integration of the pharmaceutical industry industry is relatively concentrated。For pharmaceutical manufacturers，Implementation of the new version of GMP standard，It will promote enterprises to carry out mergers and reorganizations。On December 7 last year, the Executive Meeting of the State Council discussed the "National Drug Safety Plan (2011-2015)"，Clarified the overall goal and key tasks of drug safety work during the "Twelfth Five -Year Plan" period，Emphasized to 2015，Drug production must 100%meet the new version of GMP requirements，Only 3 years left for the drug company。"A large number of companies that do not meet the GMP standards in terms of software and hardware in terms of software and hardware will not continue to produce，Bankruptcy、The possibility of merging and reorganization by large enterprises is the most likely。"He revealed，The company also has this intention，Looking forward to the merger of the acquisition to quickly become a large enterprise scale。
In addition，Get the scale advantage quickly、complementary varieties、Participate in international competition and other temptations，Chinese pharmaceutical companies also set their sights on overseas markets。Our reporter's investigation and learned，Some relevant persons in charge of pharmaceutical companies that already have a certain scale of advantages are traveling abroad all year round。"High valuation of domestic pharmaceutical companies，and some overseas pharmaceutical companies are not high，If mergers and acquisitions are achieved，For us to get some new varieties or open up overseas sales channels，It is very helpful。"The person in charge stake sports betting appof stake sports betting appthe marketing department of a listed company should be revealed。
Low industrial concentration is facing changes
Frequently carrying out the merger and reorganization action，It will help change the current status of low concentration of my country's pharmaceutical industry。
According to Wang Xuegong's introduction，Low concentration of the pharmaceutical industry in my country，Enterprise Multi -San has Stake Sports Bettingbecome one of the main problems in the development of the pharmaceutical industry。"More than 4,800 pharmaceutical manufacturers，Sales less than 50 million yuan accounted for more than 70%，13,000 medical device companies，less than 200 sales of sales of more than 100 million yuan。The top 100 companies in the top 100 pharmaceutical sales revenue in 2010 accounted for 33%of the sales revenue of the industry. "
Observed person in the pharmaceutical market, Mr. Tang's view，Although the pharmaceutical industry has experienced a large number of reorganizations and mergers in recent years，But compared with the European and American pharmaceutical market，Still compared with other domestic consumer goods markets，The concentration of the pharmaceutical industry is very low，It is difficult to expect quality incentives under the brand under this situation，Because in the face of so many manufacturers and brands，Consumers cannot form brand cognition。
and the director of the China Medical Science and Technology Achievement Transformation Center Rui Guozhong told reporters，The "Golden Ten Years" just opened is a process of industrial reconstruction and towards concentration，The result must be the increase in concentration and the multi -polarization of the industry。and mergers and acquisitions are the fastest industrial reconstruction and towards concentration、The most mainstream path，From this, the third round of mergers and acquisitions in the Chinese pharmaceutical industry，That is the era of mergers and acquisitions。
Integrated acceleration in the field of pharmaceutical business
Enterprises except the pharmaceutical industry are constantly integrating，The merger and reorganization in the field of pharmaceutical business has also started to speed up。
In the past 2011，Through continuous merger and reorganization，Sinopharm Group became stake sports betting appthe stake betting appfirst pharmaceutical company in China with more than 100 billion yuan。But，The scattered pattern of the pharmaceutical industry has not fundamentally changed，Sinopharm Group said it will continue to promote mergers and reorganization。
May 7，According to the secretary of the board of directors of the Sinopharm Group、A spokesman Shi Shengyi told reporters，Relying on the acquisition of mergers and mergers，Then copy the management system of the Chinese medicine to every new store，Then copy the management system of the Chinese medicine to every new store。
President of China Medical Business Association Fu Mingzhong also told reporters，In the next few years, the pharmaceutical industry will enter the climax period。From an international perspective，Pharmaceutical business concentration of industrialized developed countries is more than 90%，And the wholesale of the drug faster than retail，Pharmaceuticals will be relatively lagging behind wholesale。In the new medical reform environment，The state hopes to accelerate the improvement of industrial concentration and management upgrade。
